+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia Pacific Allergy Immunotherapies Market to 2027- COVID-19 Impact and Regional Analysis - By Treatment, Allergy Type, Distribution Channel, and Geography

  • ID: 5180738
  • Report
  • September 2020
  • Region: Asia Pacific
  • 115 pages
  • The Insight Partners
UP TO OFF
until Jan 15th 2021

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • ALK Abello A/S
  • Anergis
  • Circassia
  • HAL Allergy B.V.
  • Stallergenes Greer
  • MORE
The Asia Pacific allergy immunotherapies market was valued at US$ 697.5 million in 2019 and is projected to reach US$ 871.08 million by 2027; it is expected to grow at a CAGR of 11.5 % during the forecast period.

The Asia Pacific allergy immunotherapies market is expected to witness substantial growth during the forecast period owing to increasing incidence of chronic diseases, rising disposable income of individuals and improving conditions of healthcare infrastructure. However, drawbacks associated with the use of allergy immunotherapies and variations in regulatory framework across different countries in the region hamper the growth of the market.

Allergy immunotherapy is primarily aimed at reducing symptoms and symptomatic medication usage, and improving allergy-related quality of life. The allergy immunotherapy market in Asia Pacific is expected to exhibit the highest CAGR among all major regional markets due to the increased incidence of allergy in developing Asian countries such as China and India. In Asia Pacific countries, ~20-30% of the total population has more than one type of allergy. Efforts toward establishing excellent regulatory scenario for the sale of drugs through online pharmacies would boost the allergy immunotherapy business growth and development in Asia Pacific in the coming years. The growing unmet needs of novel targeted drugs used to treat the allergic conditions act as key opportunities for the growth of market players. Many companies are investing in research and development to develop targeted drugs for various allergic disorders. The introduction of more such allergen immunotherapy tablets (AITs) in potential segments helps them expand their share in the global marketplace.

The COVID-19 pandemic has harmed the Asia Pacific allergy immunotherapies market size, with small and medium-scale companies struggling to sustain their businesses in the near future. Industry leaders are now focusing on creating new business practices to deal with such crises.

The Asia Pacific allergy immunotherapies market, based on Treatment, is segmented into subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). In 2019, the SCIT segment held a larger share of the market. However, the SLIT segment is expected to grow at a higher CAGR during the forecast period. The Asia Pacific allergy immunotherapies market, based on allergy type, is segmented into allergic rhinitis, asthma, food allergy, venom allergy, and others. The allergic rhinitis segment held the greatest share of the market in 2019, and the same segment is anticipated to register the highest CAGR in the market during 2020-2027.

The Asia Pacific allergy immunotherapies market, based on distribution channel, is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. In 2019, the hospital pharmacy settings segment held the largest share of the market, and market for the same segment is expected to grow at the fastest CAGR during the forecast period.

A few of the major primary and secondary sources associated with the Asia Pacific allergy immunotherapy market report are Celsion Corporation, World Allergy Organization (WAO), Asia Pacific Association of Allergy and Asthma and Clinical Immunology (APAACI).
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • ALK Abello A/S
  • Anergis
  • Circassia
  • HAL Allergy B.V.
  • Stallergenes Greer
  • MORE
1. Introduction
1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Allergy Immunotherapies Market - By Treatment
1.3.2 Asia Pacific Allergy Immunotherapies Market - By Allergy Type
1.3.3 Asia Pacific Allergy Immunotherapies Market - By Distribution Channel
1.3.4 Asia Pacific Allergy Immunotherapies Market - By Geography

2. Asia Pacific Allergy Immunotherapies Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Allergy Immunotherapies Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Asia-Pacific - PEST Analysis
4.3 Expert Opinion

5. Asia Pacific Allergy immunotherapies Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Growing Prevalence of Allergic Disorders
5.1.2 Technological Advancements in Sublingual Dosage Formulations
5.2 Key Market Restraint
5.2.1 Drawbacks Associated with the Use of Allergy Immunotherapy
5.2.2 Regulatory Variations Across Regions
5.3 Key Market Opportunities
5.3.1 Expansion of Pharmacy across Globe
5.4 Future Trends
5.4.1 Increasing Research and Development for Drugs
5.5 Impact Analysis

6. Allergy Immunotherapies Market - Asia Pacific Analysis
6.1.1 Asia-Pacific: Allergy Immunotherapies Market - Revenue and Forecast to 2027 (USD Million)

7. Asia Pacific Allergy Immunotherapies Market Analysis- by Treatment
7.1 Overview
7.2 Allergy Immunotherapies Market Share, By Treatment, 2019 & 2027 (%)
7.3 Subcutaneous Immunotherapy (SCIT)
7.3.1 Overview
7.4 Sublingual Immunotherapy (SLIT)
7.4.1 Overview
7.4.2 Sublingual Immunotherapy (SLIT) Market Revenue and Forecasts to 2027 (US$ Million)

8. Allergy Immunotherapies Market Analysis- by Allergy Type
8.1 Overview
8.2 Allergy Immunotherapies Market Share, By Allergy Type, 2019 & 2027 (%)
8.3 Allergic Rhinitis
8.3.1 Overview
8.3.2 Allergic Rhinitis Market Revenue and Forecasts to 2027 (US$ Million)
8.4 Asthma
8.4.1 Overview
8.4.2 Asthma Market Revenue and Forecasts to 2027 (US$ Million)
8.5 Food Allergy
8.5.1 Overview
8.5.2 Food Allergy Market Revenue and Forecasts to 2027 (US$ Million)
8.6 Venom Allergy
8.6.1 Overview
8.6.2 Venom Allergy Market Revenue and Forecasts to 2027 (US$ Million)
8.7 Other Allergies
8.7.1 Overview
8.7.2 Others Market Revenue and Forecasts to 2027 (US$ Million)

9. Allergy Immunotherapies Market Analysis- by Distribution Channel
9.1 Overview
9.2 Allergy Immunotherapies Market Share, By Distribution Channel, 2019 & 2027 (%)
9.3 Hospital Pharmacy
9.3.1 Overview
9.3.2 Hospital Pharmacy Market Revenue and Forecasts to 2027 (US$ Million)
9.4 Retail Pharmacy
9.4.1 Overview
9.4.2 Retail Pharmacy Market Revenue and Forecasts to 2027 (US$ Million)
9.5 Online Pharmacy
9.5.1 Overview
9.5.2 Online PharmacyMarket Revenue and Forecasts to 2027 (US$ Million)

10. Allergy Immunotherapies Market Analysis And Forecasts To 2027 - Geographical Analysis
10.1 Asia-Pacific: Allergy Immunotherapies Market
10.1.1 Overview
10.1.2 Asia-Pacific: Allergy Immunotherapies Market - Revenue and Forecast to 2027 (USD Million)
10.1.3 Asia-Pacific Allergy Immunotherapies Market, by Treatment - Revenue and Forecast to 2027 (USD Million)
10.1.4 Asia-Pacific Allergy Immunotherapies Market, by Allergy Type - Revenue and Forecast to 2027 (USD Million)
10.1.5 Asia-Pacific Allergy Immunotherapies Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
10.1.6 Asia-Pacific: Allergy Immunotherapies Market, by Country, 2019 & 2027 (%)
10.1.7 China: Allergy Immunotherapies Market - Revenue and Forecast to 2027 (USD Million)
10.1.7.1 China: Allergy Immunotherapies Market - Revenue and Forecast to 2027 (USD Million)
10.1.7.2 China Allergy Immunotherapies Market, by Treatment - Revenue and Forecast to 2027 (USD Million)
10.1.7.3 China Allergy Immunotherapies Market, by Allergy Type - Revenue and Forecast to 2027 (USD Million)
10.1.7.4 China Allergy Immunotherapies Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
10.1.8 Japan: Allergy Immunotherapies Market - Revenue and Forecast to 2027 (USD Million)
10.1.8.1 Japan: Allergy Immunotherapies Market - Revenue and Forecast to 2027 (USD Million)
10.1.8.2 Japan Allergy Immunotherapies Market, by Treatment - Revenue and Forecast to 2027 (USD Million)
10.1.8.3 Japan Allergy Immunotherapies Market, by Allergy Type - Revenue and Forecast to 2027 (USD Million)
10.1.8.4 Japan Allergy Immunotherapies Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
10.1.9 India: Allergy Immunotherapies Market - Revenue and Forecast to 2027 (USD Million)
10.1.9.1 India: Allergy Immunotherapies Market - Revenue and Forecast to 2027 (USD Million)
10.1.9.2 India Allergy Immunotherapies Market, by Treatment - Revenue and Forecast to 2027 (USD Million)
10.1.9.3 India Allergy Immunotherapies Market, by Allergy Type - Revenue and Forecast to 2027 (USD Million)
10.1.9.4 India Allergy Immunotherapies Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
10.1.10 South Korea: Allergy Immunotherapies Market - Revenue and Forecast to 2027 (USD Million)
10.1.10.1 South Korea: Allergy Immunotherapies Market - Revenue and Forecast to 2027 (USD Million)
10.1.10.2 South Korea Allergy Immunotherapies Market, by Treatment - Revenue and Forecast to 2027 (USD Million)
10.1.10.3 South Korea Allergy Immunotherapies Market, by Allergy Type - Revenue and Forecast to 2027 (USD Million)
10.1.10.4 South Korea Allergy Immunotherapies Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
10.1.11 Australia: Allergy Immunotherapies Market - Revenue and Forecast to 2027 (USD Million)
10.1.11.1 Australia: Allergy Immunotherapies Market - Revenue and Forecast to 2027 (USD Million)
10.1.11.2 Australia Allergy Immunotherapies Market, by Treatment - Revenue and Forecast to 2027 (USD Million)
10.1.11.3 Australia Allergy Immunotherapies Market, by Allergy Type - Revenue and Forecast to 2027 (USD Million)
10.1.11.4 Australia Allergy Immunotherapies Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)

11. Impact of COVID-19 Pandemic on Asia Pacific Allergy Immunotherapies Market
11.1 Asia Pacific: Impact Assessment of COVID-19 Pandemic

12. Company Profiles
12.1 ALK-Abelló A/S
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Stallergenes Greer
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 HAL Allergy B.V.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Johnson and Johnson Services, Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Anergis
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 DBV Technologies
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Allergy Therapeutics
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments

13. Appendix
13.1 Glossary of Terms
Note: Product cover images may vary from those shown
  • HAL Allergy B.V.
  • ALK Abello A/S
  • Stallergenes Greer
  • Anergis
  • Circassia
Note: Product cover images may vary from those shown
Adroll
adroll